In a significant legal victory, Novo Nordisk announced on December 31, 2025, that China’s Supreme People’s Court had issued a final, positive ruling upholding the validity of the company’s compound patent for semaglutide.
The decision concludes a high-stakes legal battle in one of the world’s largest healthcare markets, providing Novo Nordisk with critical legal certainty for its blockbuster GLP-1 franchise, which includes the weight-loss sensation Wegovy and the type 2 diabetes treatments Ozempic and Rybelsus.
A Decisive Legal Victory
The ruling by the Supreme People’s Court affirms a previous judgment from the Beijing Intellectual Property Court. The dispute originated when the China National Intellectual Property Administration (CNIPA) initially invalidated the semaglutide compound patent following challenges from third-party generic manufacturers. Those challenges questioned the adequacy of the experimental data provided in the original patent filing.
Novo Nordisk successfully appealed the CNIPA’s decision by submitting post-filing evidence that clarified the scope and innovation of the molecule. The Beijing IP Court accepted this evidence and restored the patent, a move that the Supreme People’s Court has now finalized.
Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
Protecting Medical Innovation
This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,
This decision also strengthens confidence for foreign companies’ sustainable development in China and will motivate further development and introduction of innovative medicines for the benefit of patients.
Mike Doustdar
Market Implications and 2026 Outlook
The ruling comes at a pivotal time for Novo Nordisk. With obesity and type 2 diabetes rates rising globally, China represents a massive growth opportunity. Protecting the patent until its scheduled expiration allows the company to maintain its market share against a wave of domestic generic competitors that were preparing to launch as early as 2026.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Despite the legal win, Novo Nordisk noted that the ruling does not change its broader financial guidance. The company had previously warned investors that the scheduled patent expiry of semaglutide in several “International Operations” territories is expected to result in a low-single-digit negative impact on global sales growth in 2026. The Chinese ruling secures the patent for its remaining term but does not alter the eventual timeline for generic entry.
Last Modified:
